Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avantis Medical Systems’ Third Eye Retroscope

This article was originally published in The Gray Sheet

Executive Summary

Expanded indication for the colon cancer detection tool gains 510(k) clearance, supporting a claim for increased detection of cancerous and pre-cancerous polyps in the colon when used in conjunction with colonoscopy, the firm announces Feb. 17. The device, initially cleared in April 2007, provides physicians a backward view of the colon that complements the forward view of the colonoscope to help them visualize blind spots in the colon where cancers may be hiding, the firm explains. The Sunnyvale, Calif.-based company recently raised $10 million in a "Series C" financing to help fund a rollout of the device this year, as well as to establish U.S. centers of excellence to facilitate the launch, to collect additional data supporting clinical utility, and for sales and marketing efforts (1"The Gray Sheet" Jan. 26, 2009, p.20)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT027122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel